revenu figur prior figur
meet rais pt
messag maintain buy rate follow recent upgrad
link base increas optim regard upsid potenti key product
jakafi well prospect late-stag pipelin tweak
model estim follow meet manag last week provid
us addit insight expens alloc slower growth guidanc
long-term forecast also updat jakafi product forecast
model larger revenu contribut polycuthemia vera pv indic
rais pt
financi guidanc still come non-gaap expect flat
vs financi guidanc provid earn call later
quarter investor meet last week provid detail breakdown
expens alloc reflect updat dcf sum-of-part model valuat
manag estim spend clinic develop
late stage asset predominantli made jakafi ruxolitinib cream itacitinib
pemigatinib baricitinib
potenti gvhd expans track jakafi entri itacitinib
pdufa date jakafi agvhd set feb approv jakafi repres
first approv treatment option set manag also confirm
evalu jakafi agvhd cgvhd respect track read
year end believ posit data agvhd increment de-risk
cgvhd opportun gvhd candid itacitinib track complet
pivot phase studi evalu itacitinib agvhd year-end
cgvhd remain on-going
pemigatinib track potenti file eoy manag confirm
expect nda pemigatinib cholangiocarcinoma file eoy
addit manag expect nda pemigatinib bladder cancer
depend data continu dose cohort later frontlin studi
on-going prepar initi cholangiocarcinoma bladder cancer respect
topic ruxolitib cream like on-going pivot trial year-end decemb
initi pivot trial evalu topic ruxolitinib atop dermat follow
promis efficaci phase studi complet last year also manag confirm
plan initi phase trial vitiligo pend phase result later year
data sever jakafi-bas combin read
present jakafi parsaclisib data show efficaci benefit ad
parsaclisib jakafi treatment patient sub-optimal respons jakafi alon
data show result cohort receiv daili dose week weekli
dose thereaft data on-going daili cohort expect read
addit initi data jakafi pim- inhibitor asset jakafi
new treatment mpn expect read year
new oral asset recent enter clinic introduc new small molecul
asset investor week product recent begun
first-in-human studi base preclin profil compar
mab howev asset util uniqu mechan action intern pd-
cancer immun cell base pre-clin data manag highlight
combin potenti product futur provid bladder kidney cancer
possibl target area
page analyst certif import disclosur
increment model chang reflect updat modifi product-level sum
part dcf reflect manag guidanc split addit refin
mf pv market-specif perform jakafi
page analyst certif import disclosur
valu per share use probabl adjust free cash flow project jakafi iclusig
olumi itacitinib topic ruxolitinib use discount rate consist
commerci stage biotech compani coverag termin growth rate
rais pt base guidanc slower expect spend refin mf
pv market-specif perform jakafi
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
risk intellectu properti risk manag execut
page analyst certif import disclosur
chang fair valu acquisition-rel conting
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
